HK1211525A1 - Laquinimod and pridopidine for treating neurodegenerative disorders - Google Patents

Laquinimod and pridopidine for treating neurodegenerative disorders

Info

Publication number
HK1211525A1
HK1211525A1 HK15112317.4A HK15112317A HK1211525A1 HK 1211525 A1 HK1211525 A1 HK 1211525A1 HK 15112317 A HK15112317 A HK 15112317A HK 1211525 A1 HK1211525 A1 HK 1211525A1
Authority
HK
Hong Kong
Prior art keywords
pridopidine
laquinimod
neurodegenerative disorders
treating neurodegenerative
treating
Prior art date
Application number
HK15112317.4A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Hayden
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1211525A1 publication Critical patent/HK1211525A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Mechanical Engineering (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15112317.4A 2012-09-27 2015-12-15 Laquinimod and pridopidine for treating neurodegenerative disorders HK1211525A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706695P 2012-09-27 2012-09-27
US201361879004P 2013-09-17 2013-09-17
PCT/US2013/062482 WO2014052933A1 (en) 2012-09-27 2013-09-27 Laquinimod and pridopidine for treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
HK1211525A1 true HK1211525A1 (en) 2016-05-27

Family

ID=50339469

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15112317.4A HK1211525A1 (en) 2012-09-27 2015-12-15 Laquinimod and pridopidine for treating neurodegenerative disorders
HK16102362.8A HK1214553A1 (zh) 2012-09-27 2016-03-01 用於治療神經退行性疾病的拉喹莫德和普利多匹定

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102362.8A HK1214553A1 (zh) 2012-09-27 2016-03-01 用於治療神經退行性疾病的拉喹莫德和普利多匹定

Country Status (13)

Country Link
US (7) US20150209346A1 (xx)
EP (1) EP2900330A4 (xx)
CN (1) CN104902958A (xx)
AU (1) AU2013323131A1 (xx)
BR (1) BR112015006623A2 (xx)
CA (1) CA2884781A1 (xx)
EA (1) EA201590655A8 (xx)
HK (2) HK1211525A1 (xx)
IL (1) IL237742A0 (xx)
IN (1) IN2015DN03219A (xx)
MX (1) MX2015003608A (xx)
WO (1) WO2014052933A1 (xx)
ZA (1) ZA201502600B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
PT2146961E (pt) * 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
KR20140008297A (ko) 2010-09-03 2014-01-21 아이백스 인터내셔널 게엠베하 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
AU2014281414A1 (en) 2013-06-21 2016-01-21 Teva Pharmaceuticals International Gmbh Use of high dose pridopidine for treating Huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
KR20160110395A (ko) * 2013-12-20 2016-09-21 테바 파마슈티컬 인더스트리즈 리미티드 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3193870A4 (en) * 2014-09-16 2018-04-25 Teva Pharmaceutical Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CN109923102B (zh) 2016-08-24 2022-11-15 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
US11253594B2 (en) 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
EP3668509B1 (en) * 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
CA3137633A1 (en) * 2019-06-12 2020-12-17 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765428A (zh) * 2007-06-18 2010-06-30 A·卡尔森研究股份有限公司 多巴胺稳定剂的用途
CN102369202A (zh) * 2008-11-13 2012-03-07 链接医药公司 氮杂喹啉酮衍生物及其应用
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
BR112013014061A2 (pt) * 2010-12-07 2016-09-13 Teva Pharma uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla

Also Published As

Publication number Publication date
ZA201502600B (en) 2016-06-29
EP2900330A4 (en) 2016-05-25
CA2884781A1 (en) 2014-04-03
US20140088140A1 (en) 2014-03-27
IL237742A0 (en) 2015-05-31
IN2015DN03219A (xx) 2015-10-02
EA201590655A8 (ru) 2016-07-29
US20170319569A1 (en) 2017-11-09
EA201590655A1 (ru) 2015-12-30
BR112015006623A2 (pt) 2017-07-04
US20180250285A1 (en) 2018-09-06
WO2014052933A1 (en) 2014-04-03
AU2013323131A1 (en) 2015-05-07
US20180133209A1 (en) 2018-05-17
CN104902958A (zh) 2015-09-09
US20190117639A1 (en) 2019-04-25
US20180369228A1 (en) 2018-12-27
US20150209346A1 (en) 2015-07-30
MX2015003608A (es) 2015-06-05
HK1214553A1 (zh) 2016-07-29
EP2900330A1 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
HK1214553A1 (zh) 用於治療神經退行性疾病的拉喹莫德和普利多匹定
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
HRP20181976T1 (hr) Postupci za liječenje poremećaja gubitka kose
EP2852388A4 (en) COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
EP2953950A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
EP2903619A4 (en) PHOSPHODIESTERASE INHIBITORS FOR TREATING TASTE AND ODORAT DISORDERS
HK1213912A1 (zh) 用於治療多發性硬化及相關病症的方法和組合物
EP2860500A4 (en) DEVICE FOR PREVENTING FAKES AND CHANGES
HK1215548A1 (zh) 用於治療神經變性疾病的方法和組合物
EP2847158A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS
EP2825173A4 (en) CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISEASES AND RIBOSOMAPATHIES
IL246286A0 (en) A medical preparation for the prevention and treatment of advanced myopia.
HK1219224A1 (zh) 角結膜病症的治療劑
EP2873267A4 (en) METHODS AND DEVICE FOR AUTHENTICATION
EP2919856A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS
EP2872166A4 (en) COMPOSITIONS AND METHODS OF DETECTING, TREATING AND PREVENTING ILLNESSES AND DISORDERS
EP2723339A4 (en) COMPOUNDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES AND OTHER NEURODEGENERATIVE DISEASES
EP2928460A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY SKIN DISEASES
HK1224220A1 (zh) 治療神經退化性失調的方法
HK1209040A1 (en) Methods for treating vestibulotoxicity
EP2844265A4 (en) POMEGRANATE OIL FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES
IL238363A0 (en) Methods for treating eye diseases
AU2012904982A0 (en) Device for treating respiratory disorders